NCT01417351

Brief Summary

Researchers at the USDA Western Human Nutrition Research Center and clinicians at UC Davis Medical Center are currently conducting a study on the effects of vitamin D supplementation during pregnancy on maternal health and immune function. The investigators believe that vitamin D supplementation at levels greater than the current recommendation is beneficial for maternal health during pregnancy. In particular, there is evidence that vitamin D deficiency during pregnancy puts women at greater risk for diseases like pre-eclampsia, which may be due to an imbalance in immune function at the placenta. This randomized, double-blind study is designed to test this hypothesis. Pregnant women who participate in the study receive either 400 IU or 2,000 IU of vitamin D per day for the duration of their pregnancy. The investigators will collect blood at three time points during pregnancy (16-20 weeks, 26-28 weeks, 36 weeks gestation) for analysis of immune function and vitamin D status. The investigators are also collecting data on clinical parameters, such as blood pressure and glucose tolerance.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Aug 2010

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2010

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

August 12, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 16, 2011

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2013

Completed
Last Updated

July 23, 2013

Status Verified

July 1, 2013

Enrollment Period

2.8 years

First QC Date

August 12, 2011

Last Update Submit

July 22, 2013

Conditions

Keywords

pregnancyimmune function

Outcome Measures

Primary Outcomes (1)

  • Change in T-cell cytokine expression

    Inflammatory and regulatory cytokines will be measured in cultured T-cells by flow cytometry.

    16-20 wks, 26-28 wks, and 36 wks gestation

Secondary Outcomes (3)

  • Change in Vitamin D status

    16-20 wks, 26-28 wks, 36 wks gestation

  • Change in innate immune function

    16-20 wks, 26-28 wks, 36 wks gestation

  • Change in blood pressure

    16-20 wks, 26-28 wks, 36 wks gestation

Study Arms (2)

400 IU Vitamin D3

PLACEBO COMPARATOR

Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.

Dietary Supplement: 400 IU vitamin D3

2,000 IU Vitamin D3

EXPERIMENTAL

Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.

Dietary Supplement: 2,000 IU Vitamin D3

Interventions

400 IU vitamin D3DIETARY_SUPPLEMENT

Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.

400 IU Vitamin D3
2,000 IU Vitamin D3DIETARY_SUPPLEMENT

Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.

2,000 IU Vitamin D3

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Pregnant women
  • Less than 20 weeks gestation
  • Over 18 years of age
  • Able to swallow nutritional supplements

You may not qualify if:

  • Use of medications known to affect vitamin D metabolism
  • Diagnosis of type 1 diabetes
  • History of thyroid, renal, or liver disease
  • Problems with digestion or absorption

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

USDA-Western Human Nutrition Research Center

Davis, California, 95616, United States

Location

UC Davis Medical Center Obstetrics & Gynecology

Sacramento, California, 95817, United States

Location

Related Publications (2)

  • Palacios C, Kostiuk LL, Cuthbert A, Weeks J. Vitamin D supplementation for women during pregnancy. Cochrane Database Syst Rev. 2024 Jul 30;7(7):CD008873. doi: 10.1002/14651858.CD008873.pub5.

  • Zerofsky MS, Jacoby BN, Pedersen TL, Stephensen CB. Daily Cholecalciferol Supplementation during Pregnancy Alters Markers of Regulatory Immunity, Inflammation, and Clinical Outcomes in a Randomized Controlled Trial. J Nutr. 2016 Nov;146(11):2388-2397. doi: 10.3945/jn.116.231480. Epub 2016 Sep 21.

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

Cholecalciferol

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

CholestenesCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsSterolsVitamin DSecosteroidsMembrane LipidsLipids

Study Officials

  • Charles B Stephensen, PhD

    USDA, ARS, Western Human Nutrition Research Center

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 12, 2011

First Posted

August 16, 2011

Study Start

August 1, 2010

Primary Completion

May 1, 2013

Study Completion

May 1, 2013

Last Updated

July 23, 2013

Record last verified: 2013-07

Locations